BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine

Published:2024-06 Issue: Volume:592 Page:216919
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Miller Aubrey L.,Fehling Samuel C.,Vance Rebecca B.,Chen Dongquan,Brown Eric Josh,Hossain M. Iqbal,Heard Eric O.^ORCID,Andrabi Shaida A.,Wang Hengbin^ORCID,Yang Eddy S.^ORCID,Buchsbaum Donald J.^ORCID,van Waardenburg Robert C.A.M.^ORCID,Bellis Susan L.,Yoon Karina J.^ORCID

Funder

O'Neal Comprehensive Cancer Center at UAB

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Reference58 articles.

1. Advances in surgery and (neo) adjuvant therapy in the management of pancreatic cancer;Liu,2024

2. Cancer Facts & Figures 2023,2023

3. Taxane anticancer agents: a patent perspective;Ojima;Expert Opin. Ther. Pat.,2016

4. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane(R)) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer;Saif;JOP,2013

5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N. Engl. J. Med.,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA repair status as a guide for pancreatic ductal adenocarcinoma treatment, an old view for a new future;Cancer Letters;2024-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP